real-time news and commentary for investors
Friday, Sep 6
Johnson & Johnson reportedly shopping its blood-testing division
- Johnson & Johnson (JNJ +0.7%) is making the rounds to companies that might be interested in buying its blood-testing division, which could fetch around $5B.
- JNJ's Ortho Clinical Diagnostics unit makes tests that can reveal a patient's blood type and screen for viruses like HIV and hepatitis C. It also makes tests that help diagnose a heart attack and assess damage to the heart.
- The testing business is part of a $46B world-wide market for in vitro diagnostics that is growing 6% - 7% a year.
- A potential deal could be wrapped up by as early as the year's end.